Rocaltrol: Uses, Dosage & Side Effects
The biologically active form of vitamin D3 (calcitriol) used to treat secondary hyperparathyroidism, renal osteodystrophy, established postmenopausal osteoporosis, hypoparathyroidism and vitamin D-dependent rickets
Rocaltrol (calcitriol) is the biologically active form of vitamin D3, meaning it can directly influence calcium and phosphate metabolism without first being activated in the body. It is prescribed in conditions where calcium balance is disturbed – particularly in chronic kidney disease, parathyroid gland disorders and certain forms of osteoporosis. By binding to the nuclear vitamin D receptor (VDR), calcitriol increases intestinal calcium absorption, normalizes serum calcium, suppresses parathyroid hormone secretion and supports bone mineralization. Because of its potent and immediate effect, Rocaltrol requires careful monitoring of blood calcium and phosphate during treatment, and patients must avoid uncontrolled intake of additional vitamin D or calcium supplements. It is available only on prescription as 0.25 or 0.5 microgram soft capsules.
Quick Facts: Rocaltrol
Key Takeaways
- Rocaltrol contains calcitriol, the biologically active form of vitamin D3, which acts directly on the vitamin D receptor without requiring activation by the kidneys – this makes it particularly useful in advanced kidney disease.
- It is used to treat secondary hyperparathyroidism and renal osteodystrophy in chronic kidney disease (including dialysis), established postmenopausal osteoporosis, hypoparathyroidism, pseudohypoparathyroidism and vitamin D-dependent rickets.
- The principal risk with Rocaltrol is hypercalcemia (high blood calcium), which can cause weakness, confusion, kidney damage, cardiac arrhythmias and soft-tissue calcification; regular blood and urine monitoring is essential throughout treatment.
- Rocaltrol interacts with several medicines – thiazide diuretics, digoxin, magnesium-containing antacids, cholestyramine, phenytoin, phenobarbital, ketoconazole and systemic corticosteroids – so a complete medication review before starting therapy is important.
- Patients should not take additional vitamin D supplements, cod liver oil or high-dose calcium preparations during treatment, and must follow their doctor’s advice strictly about diet and fluid intake to minimize the risk of hypercalcemia.
What Is Rocaltrol and What Is It Used For?
Rocaltrol is the brand name for calcitriol, also known chemically as 1,25-dihydroxycholecalciferol or 1,25(OH)2D3. It represents the final, physiologically active product of vitamin D metabolism in the human body. Ordinary vitamin D (cholecalciferol or ergocalciferol) obtained from sunlight, food or supplements is inactive. It is first hydroxylated in the liver to form 25-hydroxyvitamin D (calcifediol) – the marker measured in routine vitamin D blood tests – and then further hydroxylated in the kidneys to form calcitriol, the hormone that actually binds to the vitamin D receptor (VDR) and regulates mineral metabolism.
Because Rocaltrol delivers calcitriol directly, it bypasses the two enzymatic activation steps entirely. This is particularly valuable when one of those steps is impaired, as happens in chronic kidney disease (CKD). As kidney function declines, the renal enzyme 1α-hydroxylase (CYP27B1) becomes less efficient, leading to a progressive deficiency of active vitamin D. The resulting drop in calcium absorption from the gut, combined with phosphate retention, triggers a rise in parathyroid hormone (PTH) and a cascade of complications collectively known as chronic kidney disease-mineral and bone disorder (CKD-MBD). Rocaltrol breaks this cycle at the most downstream point.
After Rocaltrol is absorbed and reaches tissues, calcitriol binds with high affinity to the nuclear vitamin D receptor. This complex translocates to the cell nucleus, dimerizes with the retinoid X receptor (RXR) and binds to vitamin D response elements on DNA, thereby regulating the transcription of hundreds of genes involved in calcium homeostasis, immune function and cell differentiation. The three most clinically important effects are: (1) increased absorption of calcium and phosphate from the small intestine via up-regulation of transport proteins such as TRPV6 and calbindin; (2) mobilization of calcium from bone in cooperation with parathyroid hormone; and (3) direct suppression of parathyroid hormone synthesis and secretion by the parathyroid glands.
Rocaltrol is approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and regulatory authorities in most countries worldwide for the following indications:
- Secondary hyperparathyroidism and renal osteodystrophy in chronic kidney disease: Rocaltrol is used to normalize calcium levels and suppress elevated PTH in adult and pediatric patients with moderate to severe CKD, including those on maintenance hemodialysis or peritoneal dialysis. Untreated, secondary hyperparathyroidism accelerates bone loss, contributes to vascular calcification and increases cardiovascular mortality.
- Hypoparathyroidism and pseudohypoparathyroidism: In patients whose parathyroid glands do not produce enough PTH (e.g., after thyroid or parathyroid surgery, autoimmune disease or the rare inherited condition DiGeorge syndrome), or whose tissues do not respond normally to PTH, calcitriol substitutes for the missing signal and restores normal calcium absorption and serum calcium.
- Vitamin D-dependent rickets (type I and type II): These rare genetic disorders impair calcitriol production or VDR function. Type I rickets (due to CYP27B1 mutations) responds well to physiological doses of Rocaltrol, while type II rickets (due to VDR mutations) may require higher doses.
- Established postmenopausal osteoporosis: In selected patients, Rocaltrol has been shown to reduce the rate of vertebral fractures by improving intestinal calcium absorption and bone quality, particularly in those with impaired calcium absorption or relative calcitriol deficiency.
Beyond these labeled indications, calcitriol has also been studied and prescribed off-label in certain dermatological conditions (such as psoriasis, where topical analogues are more common), in patients with familial hypophosphatemic vitamin D-resistant rickets and in selected cases of hypocalcemia due to anticonvulsant therapy or prolonged corticosteroid use. Off-label use should always be guided by a specialist physician.
The distinction between Rocaltrol (calcitriol) and standard vitamin D supplements (cholecalciferol/ergocalciferol) is clinically critical. Standard vitamin D depends on healthy liver and kidney function for activation and has a wide safety margin. Calcitriol is already active, has a narrow therapeutic window and can cause rapid, dangerous hypercalcemia if over-dosed. The two are not interchangeable and switching between them should always be done by a physician.
What Should You Know Before Taking Rocaltrol?
Contraindications
Rocaltrol must not be used in the following situations, as the risk of serious harm clearly outweighs any potential benefit:
- Hypersensitivity: Do not take Rocaltrol if you are allergic to calcitriol, other vitamin D analogues or any of the excipients, including butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) or, in some formulations, sorbitol.
- Hypercalcemia: Rocaltrol must not be used in patients with a current serum calcium level above the normal range. Giving additional calcitriol in this situation can precipitate cardiac arrhythmias, acute kidney injury and neurological deterioration.
- Vitamin D toxicity: Any clinical or laboratory evidence of existing vitamin D toxicity (metastatic calcification, marked hypercalciuria, nephrocalcinosis) is a contraindication until the condition has been fully resolved.
- Concurrent high-dose vitamin D therapy: Rocaltrol should not be used together with other prescription-strength vitamin D preparations unless specifically directed by a physician in unusual clinical scenarios.
Warnings and Precautions
Hypercalcemia (serum calcium above the upper limit of normal) is the most important adverse reaction to Rocaltrol. Symptoms include weakness, fatigue, headache, nausea, vomiting, constipation, increased thirst, frequent urination, bone or muscle pain, confusion and – if severe – cardiac arrhythmias and coma. Sustained hypercalcemia can cause nephrocalcinosis, vascular calcification and irreversible kidney damage. Serum calcium and phosphate should be monitored closely, particularly during dose titration.
Before and during treatment with Rocaltrol, inform your doctor if any of the following apply to you:
- Kidney disease or kidney stones: Even in patients being treated for CKD, Rocaltrol requires careful dose titration and monitoring of serum calcium, phosphate, alkaline phosphatase, PTH and, where feasible, urinary calcium. A history of calcium-containing kidney stones requires particular caution.
- Heart disease: In patients taking digoxin or other cardiac glycosides, even modest elevations of serum calcium can precipitate life-threatening arrhythmias. ECG monitoring and cardiology input may be needed.
- Granulomatous diseases: Sarcoidosis, tuberculosis and some lymphomas are associated with extrarenal production of calcitriol by activated macrophages. Exogenous calcitriol in this setting markedly increases the risk of hypercalcemia and should be used only with extreme caution.
- Hyperphosphatemia: Before starting Rocaltrol in CKD, serum phosphate should be controlled using dietary measures and phosphate binders, because calcitriol further increases intestinal phosphate absorption and can worsen phosphate retention.
- Immobilized patients: Bed rest or prolonged immobilization increases bone resorption and the risk of hypercalcemia. Rocaltrol therapy in such patients should be carefully re-evaluated.
- Elderly patients: Older patients are more likely to have reduced kidney function, multiple comorbidities and concomitant medications. Lower starting doses and more frequent monitoring are appropriate.
- Dietary calcium and fluid: Your doctor will give you specific instructions about how much calcium to take in from food and supplements, and about maintaining adequate fluid intake. Do not add non-prescribed calcium tablets, mineral waters or calcium-fortified foods on your own initiative.
Your medical team will arrange a schedule of blood and urine tests to detect hypercalcemia and hyperphosphatemia early. In the first weeks of therapy, calcium may be checked weekly; once stabilized, testing intervals are typically extended to every 1–3 months, with additional checks after any dose adjustment.
Other Medications
Tell your doctor and pharmacist about every medication, herbal product and supplement you are taking or plan to start. Many commonly prescribed drugs – including thiazide diuretics, digoxin, corticosteroids and anticonvulsants – interact meaningfully with calcitriol. Self-medication with calcium, vitamin D or magnesium preparations during Rocaltrol therapy is especially dangerous and should always be avoided without medical advice.
Pregnancy and Breastfeeding
Rocaltrol should be used during pregnancy only when the potential benefit to the mother clearly outweighs the potential risk to the fetus. Hypercalcemia during pregnancy has been associated with suppression of fetal parathyroid function, mental and physical retardation, supravalvular aortic stenosis and retinopathy in the neonate. Animal studies have shown teratogenic effects at doses several-fold higher than the recommended human dose. If Rocaltrol is continued during pregnancy, maternal serum calcium must be monitored particularly carefully.
Calcitriol and its metabolites are excreted in human breast milk. Breastfeeding mothers taking Rocaltrol should monitor their own calcium level and also have the infant’s calcium checked periodically, especially in premature or low-birth-weight infants. In most cases, breastfeeding can continue with careful supervision.
Both men and women of reproductive age should discuss family planning with their physician before starting Rocaltrol. If you become pregnant during therapy, inform your doctor promptly so that monitoring can be adjusted.
Driving and Operating Machinery
Rocaltrol itself has no direct sedative or psychoactive effects, but uncorrected hypercalcemia can cause dizziness, fatigue, weakness and, in severe cases, confusion. If you experience any of these symptoms, do not drive or operate heavy machinery and contact your doctor for urgent review.
Important Information About Ingredients
Rocaltrol soft capsules contain calcitriol dissolved in a fractionated triglyceride vehicle with the antioxidants butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). The gelatin shell contains glycerol and may contain the coloring agents iron oxide red or yellow. Some formulations contain small amounts of sorbitol; patients with rare hereditary fructose intolerance should inform their doctor. BHA and BHT may very rarely cause local skin or mucous membrane reactions.
How Does Rocaltrol Interact with Other Drugs?
Drug interactions with Rocaltrol occur through several mechanisms: by altering calcium or phosphate balance, by modifying the metabolism of calcitriol via the cytochrome P450 enzyme CYP24A1 and related pathways, or by changing the gastrointestinal absorption of calcitriol itself. A complete medication review before starting therapy and at every dose change is essential. Particular care is needed in patients taking multiple medications, older adults and those with chronic kidney disease, who typically require polypharmacy.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Thiazide diuretics (e.g., hydrochlorothiazide, bendroflumethiazide) | Decreased urinary calcium excretion, additive risk of hypercalcemia | Monitor calcium closely; dose reduction of Rocaltrol may be required |
| Digoxin and other cardiac glycosides | Hypercalcemia potentiates the cardiotoxic effects of digitalis; risk of serious arrhythmias | Use with caution; maintain strict calcium control and monitor ECG/digoxin levels |
| Magnesium-containing antacids (e.g., some heartburn preparations) | Risk of hypermagnesemia, particularly in patients on dialysis | Avoid in CKD patients; use calcium- or aluminum-based phosphate binders instead |
| Other vitamin D preparations (cholecalciferol, ergocalciferol, alfacalcidol, paricalcitol) | Additive vitamin D activity; greatly increased risk of hypercalcemia and vitamin D toxicity | Do not combine without explicit specialist advice |
| Calcium supplements and high-dose calcium-containing phosphate binders | Enhanced intestinal calcium absorption, risk of hypercalcemia and vascular calcification | Dose of calcium and of Rocaltrol must be coordinated by the physician |
Minor and Moderate Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Phenytoin, phenobarbital, carbamazepine (CYP450 inducers) | Accelerated hepatic metabolism of calcitriol; reduced plasma levels and efficacy | Dose of Rocaltrol may need to be increased; monitor calcium and PTH |
| Systemic corticosteroids (prednisone, dexamethasone) | Reduce intestinal calcium absorption and antagonize the effects of calcitriol; long-term use causes bone loss | Rocaltrol dose may need adjustment; bone density monitoring advisable |
| Cholestyramine, colestipol (bile acid sequestrants) | Reduced intestinal absorption of calcitriol (as of fat-soluble vitamins generally) | Separate administration by at least 4 hours; monitor calcium response |
| Ketoconazole and other strong CYP24A1 inhibitors | Variable effects on calcitriol levels; possible prolonged effect | Monitor calcium during initiation and dose changes |
| Orlistat (weight-loss lipase inhibitor) | Reduced intestinal absorption of fat-soluble vitamin D metabolites | Separate dosing; monitor calcium and 25-OH-D if possible |
| Sevelamer, lanthanum carbonate (non-calcium phosphate binders) | Help control serum phosphate without adding calcium load | Preferred in patients with CKD on calcitriol when calcium load is a concern |
Herbal and over-the-counter products can also interact with Rocaltrol. Products containing significant amounts of vitamin D or calcium (such as cod liver oil, multivitamins and some calcium-fortified foods) can contribute to hypercalcemia. St John’s wort is a CYP450 inducer and can theoretically reduce calcitriol levels. Always bring a complete list of what you take – including supplements – to every medical and pharmacy appointment.
What Is the Correct Dosage of Rocaltrol?
Rocaltrol dosing is never “one size fits all”. The optimal dose depends on the underlying condition, the patient’s age, kidney function, dietary calcium intake, concomitant medications and, most importantly, the response of serum calcium and phosphate. Your physician will start at the lowest reasonable dose, then adjust gradually after checking laboratory values. Never change the dose yourself, and do not attempt to “catch up” for missed doses by doubling up.
Adults
Chronic Kidney Disease (Pre-dialysis and Dialysis)
Indication: Secondary hyperparathyroidism and renal osteodystrophy in adult CKD patients
Starting dose: 0.25 microgram once daily; may start every other day in patients with normal or only slightly reduced serum calcium
Titration: Increase by 0.25 microgram every 2–4 weeks, based on serum calcium, phosphate and PTH
Typical maintenance: 0.25–1.0 microgram per day; some hemodialysis patients may require up to 1.5 microgram per day, divided or given as pulse therapy
Hypoparathyroidism and Pseudohypoparathyroidism
Indication: Adult patients with reduced parathyroid hormone activity
Starting dose: 0.25 microgram in the morning
Titration: Increase after 2–4 weeks if serum calcium remains below the target range
Typical maintenance: 0.5–2.0 microgram per day, often combined with oral calcium supplements
Established Postmenopausal Osteoporosis
Indication: Selected patients in whom calcitriol is judged clinically appropriate
Dose: 0.25 microgram twice daily (morning and evening)
Patients should maintain a moderate dietary calcium intake (approximately 800 mg per day) and have serum and urinary calcium checked at 4 weeks, 3 months and 6 months, then every 6 months.
Vitamin D-Dependent Rickets
Type I: 0.25–0.5 microgram per day (often lower in children)
Type II: May require higher doses, sometimes 5–10 microgram per day, under specialist supervision
Children
Rocaltrol is used in children for conditions such as renal osteodystrophy, hypoparathyroidism and vitamin D-dependent rickets under specialist supervision. Pediatric dosing is weight-based and requires particular care because children have a smaller margin of safety. Typical starting doses are 0.05 microgram/kg/day in infants and younger children, titrated against serum calcium, phosphate and alkaline phosphatase. In children with CKD, serum PTH and growth should also be monitored. Calcitriol can affect growth plates if hypercalcemia is not corrected promptly, so monitoring intervals are typically shorter than in adults.
Elderly
Older adults often have reduced kidney function, altered body composition and concurrent medications that affect calcium balance. Start at the lowest recommended dose (0.25 microgram every other day or once daily) and titrate more cautiously. Baseline serum creatinine, calcium, phosphate and 25-OH-D should be checked, and monitoring intervals should be shortened during titration. A history of falls, previous fractures and risk of immobilization should also be considered.
Renal or Hepatic Impairment
Although Rocaltrol is specifically valuable in renal impairment, dosing must still reflect the degree of renal failure. In severe hepatic impairment, calcitriol metabolism may be altered; dose reductions and more frequent monitoring are advisable. Calcitriol is not significantly removed by hemodialysis, so no supplementary dose is needed after a dialysis session.
Missed Dose
If you forget a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and take the next dose at the usual time. Never double up: taking two doses close together can cause abrupt hypercalcemia. If you miss several doses, contact your doctor for advice rather than trying to catch up on your own.
Overdose
Because calcitriol is the active vitamin D hormone, overdose is a medical emergency. The clinical picture is that of acute hypercalcemia: anorexia, nausea, vomiting, constipation, muscle weakness, polyuria, polydipsia, dehydration, confusion and, in severe cases, cardiac arrhythmias, coma and acute kidney injury. Laboratory findings may include markedly elevated serum calcium, hyperphosphatemia, elevated urinary calcium and, later, metastatic calcifications.
Treatment includes immediate discontinuation of Rocaltrol and of any calcium supplements, aggressive rehydration with intravenous saline, loop diuretics (not thiazides) to enhance calcium excretion, and in severe cases bisphosphonates, calcitonin, glucocorticoids or dialysis against a low-calcium dialysate. Because of the long biological half-life of calcitriol (3–5 days), serum calcium must be followed for at least a week after the last dose. If you or someone else has taken too many Rocaltrol capsules, contact your local poisons centre or emergency services immediately.
How to Take Rocaltrol
Rocaltrol capsules are taken by mouth with a glass of water. They may be taken with or without food, although taking the capsule with a small fat-containing meal may slightly enhance absorption. Swallow the capsule whole; do not open, chew or crush it. Try to take your dose at the same time each day to maintain steady plasma levels. Keep a calendar or use a pill organizer if you find it easy to forget doses, and do not stop therapy abruptly without medical advice, as abrupt discontinuation can precipitate rebound hypocalcemia.
Because the therapeutic window of calcitriol is narrow, your medical team will rely on laboratory tests – not symptoms – to adjust the dose. Do not skip your scheduled blood tests, even if you feel well. Early laboratory changes allow dose adjustment before any symptoms of hypercalcemia appear.
What Are the Side Effects of Rocaltrol?
Like all medicines, Rocaltrol can cause side effects, although not all patients experience them. Unlike many drugs, most adverse reactions to calcitriol are an expected consequence of its main pharmacological action – raising serum calcium – rather than of “off-target” toxicity. This means that careful dose titration and regular laboratory monitoring can prevent the majority of serious side effects before they occur.
The side effects of calcitriol are conventionally divided into those caused by acute or chronic hypercalcemia and those caused by direct drug hypersensitivity or excipient-related reactions.
Early Symptoms of Hypercalcemia
Early hypercalcemia symptoms are often non-specific and easy to miss. Report any of the following to your doctor promptly, particularly during the first weeks of treatment or after a dose increase: weakness, tiredness, headache, nausea, vomiting, dry mouth, metallic taste, loss of appetite, abdominal cramps, muscle aches or bone pain. Constipation is particularly common and can be the first sign.
Late Symptoms of Hypercalcemia
If hypercalcemia continues uncorrected, more serious symptoms and signs can develop over days or weeks. These include marked thirst and increased urination (caused by nephrogenic diabetes insipidus), anorexia and weight loss, high blood pressure, cardiac arrhythmias, pruritus (itching), red eyes (band keratopathy), sensitivity to light, runny nose, decreased libido and, eventually, confusion, apathy, depression and in rare cases overt psychosis. Chronic hypercalcemia can cause nephrocalcinosis and irreversible kidney damage.
Frequency of Adverse Reactions
Very Common
May affect more than 1 in 10 people
- Hypercalcemia (high blood calcium) – dose-dependent, usually detected by laboratory testing before symptoms develop
- Elevated serum phosphate levels (hyperphosphatemia), especially in patients with CKD
Common
May affect up to 1 in 10 people
- Headache
- Nausea and vomiting
- Constipation
- Abdominal pain
- Dry mouth and metallic taste
- Muscle weakness and muscle pain (myalgia)
- Bone pain
- Fatigue and malaise
- Elevated urinary calcium (hypercalciuria)
Uncommon
May affect up to 1 in 100 people
- Loss of appetite (anorexia)
- Increased thirst (polydipsia) and urination (polyuria)
- Itching (pruritus) and skin rash
- Elevated blood urea nitrogen
- Elevated liver enzymes (ALT, AST)
- Mild weight loss
- Urinary tract infection (secondary to increased urinary calcium)
- Runny nose (rhinorrhea)
Rare
May affect up to 1 in 1,000 people
- Cardiac arrhythmias (particularly when combined with digitalis)
- Nephrocalcinosis (calcium deposits in the kidney)
- Vascular and soft-tissue calcification
- Hypertension (elevated blood pressure)
- Band keratopathy (corneal calcium deposits)
- Psychomotor changes: apathy, depression, confusion
- Sensory disturbances, sensitivity to light
Not Known
Frequency cannot be estimated from available data
- Hypersensitivity reactions to the active substance or excipients
- Acute psychiatric reactions in severely hypercalcemic patients
- Growth plate disturbances in rapidly growing children if hypercalcemia is not corrected
- Exacerbation of granulomatous disease (e.g., sarcoidosis)
Patients on hemodialysis or peritoneal dialysis are at particular risk for vascular calcification and cardiac events if hypercalcemia and hyperphosphatemia are not controlled. Modern practice aims to keep the serum calcium-phosphate product within recommended KDIGO targets and may favor non-calcium phosphate binders alongside Rocaltrol.
If you experience any side effects, including those not listed here, tell your doctor or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch programme in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to help monitor the ongoing benefit-risk profile of Rocaltrol.
How Should Rocaltrol Be Stored?
Correct storage is important because calcitriol is a sensitive molecule that can degrade when exposed to light, air or humidity. Follow these instructions to ensure that each capsule contains the full labeled dose:
- Temperature: Store below 25°C (77°F). Do not refrigerate (cold temperatures do not improve stability and may cause condensation inside the pack).
- Light protection: Keep the capsules in the original blister or bottle. Calcitriol is light-sensitive and should not be transferred to transparent pill organizers for more than a few days.
- Moisture: Do not store in bathrooms, near kitchen sinks or in other humid areas. The soft gelatin shell can become sticky or damaged by excessive humidity.
- Safe keeping: Keep out of sight and reach of children. Accidental ingestion of even a few capsules can cause hypercalcemia in a child.
- Expiry: Do not use after the expiry date printed on the carton and blister. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via wastewater or household waste. Return unused or expired capsules to your pharmacy for environmentally safe destruction.
If your capsules look damaged, discolored or unusually soft, do not take them. Contact your pharmacy for replacement and advice on whether any missed dose requires a call to your doctor.
What Does Rocaltrol Contain?
Active Substance
The active substance is calcitriol (chemically: 1α,25-dihydroxycholecalciferol; molecular formula C27H44O3; molecular weight 416.6 g/mol). Each soft capsule contains either 0.25 microgram or 0.5 microgram of calcitriol, depending on the strength prescribed. Note that one microgram (µg) of calcitriol is equivalent to approximately 40 International Units (IU), although this conversion differs from the conversion used for inactive vitamin D3.
Inactive Ingredients (Excipients)
- Fractionated triglycerides (medium-chain triglyceride vehicle)
- Butylated hydroxyanisole (BHA, E320) – antioxidant
- Butylated hydroxytoluene (BHT, E321) – antioxidant
- Gelatin (capsule shell)
- Glycerol (capsule plasticizer)
- Purified water
- Coloring agents, such as iron oxide red (E172) and/or iron oxide yellow (E172), depending on the strength
Appearance and Packaging
Rocaltrol is a small, oval, soft gelatin capsule. The 0.25 microgram capsule is typically a pale reddish-orange color, while the 0.5 microgram capsule is a stronger reddish-brown. Capsules are supplied in blister strips, usually in packs of 20, 30, 50 or 100 capsules, although pack sizes vary by country. The strength is printed on both the blister and the outer carton; always check the strength before taking the capsule.
Marketing Authorization Holder and Manufacturer
Rocaltrol was originally developed by F. Hoffmann-La Roche Ltd. (Basel, Switzerland) and has been marketed under this brand in Europe, the United States and other regions for several decades. Calcitriol is now also available as a generic under various other trade names. Marketing authorizations, pack sizes and specific excipients may differ between countries; always check the most recent local patient information leaflet (PIL) or Summary of Product Characteristics (SmPC) supplied with your medication.
Frequently Asked Questions About Rocaltrol
Rocaltrol (calcitriol) is the active form of vitamin D3. It is used to treat low blood calcium and its complications in several conditions: secondary hyperparathyroidism and renal osteodystrophy in chronic kidney disease (including dialysis), hypoparathyroidism and pseudohypoparathyroidism, established postmenopausal osteoporosis, and vitamin D-dependent rickets (types I and II). Because it is already active, it does not need to be converted by the kidneys, which makes it uniquely valuable in patients with kidney failure.
Calcitriol reaches peak plasma levels within 3 to 6 hours after an oral dose and starts increasing intestinal calcium absorption within hours. However, the full effect on serum calcium, parathyroid hormone and bone markers is typically assessed over 2 to 6 weeks of consistent daily dosing. The plasma half-life is 5 to 8 hours, but biological effects on calcium metabolism last 3 to 5 days – this is why dose changes are made slowly, with laboratory checks at each step.
No. You should not take additional vitamin D supplements – whether cholecalciferol, ergocalciferol, calcitriol or analogues such as alfacalcidol or paricalcitol – without explicit medical instruction. Combining preparations greatly increases the risk of hypercalcemia. Non-prescription multivitamins, cod liver oil and calcium- or vitamin D-fortified foods can also contribute cumulatively. Tell your doctor and pharmacist about everything you take, including supplements, so that total vitamin D intake can be managed safely.
Symptoms of high calcium include nausea, vomiting, constipation, thirst, increased urination, weakness, confusion, bone or muscle pain and, in severe cases, cardiac arrhythmias. If a blood test shows elevated calcium, your doctor will usually stop Rocaltrol temporarily, review dietary calcium intake and check for contributing factors (dehydration, other medications). Once calcium returns to normal, therapy may be restarted at a lower dose with more frequent monitoring. Severe hypercalcemia is a medical emergency and may require intravenous fluids, diuretics or dialysis.
Rocaltrol should only be used during pregnancy if the benefit to the mother clearly outweighs the potential risk to the fetus. Maternal hypercalcemia can cause suppression of fetal parathyroid function, mental and physical retardation and aortic valve abnormalities in the newborn. Calcitriol is excreted in breast milk; breastfeeding mothers on Rocaltrol should have both their own and their infant’s serum calcium monitored. Always discuss pregnancy planning, pregnancy and breastfeeding with your doctor before starting or continuing therapy.
Standard vitamin D preparations (cholecalciferol/D3 and ergocalciferol/D2) are inactive precursors that must be hydroxylated in the liver and kidneys to become active. Alfacalcidol (1α-hydroxycholecalciferol) still requires one additional hydroxylation step in the liver. Rocaltrol contains calcitriol, the fully active form that acts directly on the vitamin D receptor. This makes Rocaltrol much more potent, faster-acting and riskier if overdosed. The three types of preparations are not interchangeable on a microgram-for-microgram basis and switching between them should only be done under medical supervision.
Do not stop Rocaltrol without medical advice. In chronic conditions such as hypoparathyroidism or CKD, Rocaltrol is usually a long-term or lifelong therapy because the underlying problem (absent parathyroid hormone or failing renal activation of vitamin D) does not resolve. Stopping treatment abruptly can cause rapid rebound hypocalcemia, with symptoms such as muscle cramps, tingling, seizures or cardiac arrhythmias. If a temporary pause is needed because of hypercalcemia, your doctor will typically plan a controlled re-introduction at a lower dose.
References
- U.S. Food and Drug Administration (FDA). Rocaltrol (calcitriol) Capsules and Oral Solution – Prescribing Information. Revised 2024. Available from the FDA Drugs@FDA database.
- European Medicines Agency (EMA). Calcitriol – Summary of Product Characteristics. National authorizations, most recently reviewed 2025.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2024;14(1):1–97.
- Joint Formulary Committee. British National Formulary (BNF). Calcitriol monograph. London: BMJ Group and Pharmaceutical Press; 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Bover J, Ureña-Torres P, Lloret MJ, et al. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from pills to diet. Expert Opin Pharmacother. 2021;22(11):1409–1427. doi:10.1080/14656566.2020.1862796.
- Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in CKD. Am J Nephrol. 2022;54:47–60.
- Tsuprykov O, Chen X, Hocher CF, Skoblo R, Yin L, Hocher B. Why should we measure free 25(OH) vitamin D? J Steroid Biochem Mol Biol. 2018;180:87–104. doi:10.1016/j.jsbmb.2017.11.014.
- Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. doi:10.1056/NEJMra070553.
- Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2019;40(4):1109–1151. doi:10.1210/er.2018-00126.
- Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273–2283.
- Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992;326(6):357–362.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in nephrology, endocrinology and clinical pharmacology.
Medical Content
iMedic Nephrology and Endocrinology Editorial Team – specialist physicians with clinical experience in CKD-MBD, calcium metabolism and vitamin D therapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, KDIGO and BNF guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.